147 results about "Orally disintegrating tablet" patented technology

The present disclosure provides a method of treating a symptom or preventing a symptom of generalized anxiety disorder comprising administering an orally disintegrating tablet comprising LSD, or a salt thereof, to a subject in need thereof.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention belongs to the technical field of medicines, and particularly relates to a fenerenone orally disintegrating tablet and a preparation method thereof. The active component of the fenerenone orally disintegrating tablet is fenerenone, and the fenerenone orally disintegrating tablet comprises the following components in percentage by weight: 10-15% of fenerenone, 10-15% of magnesium stearate, 10-15% of magnesium stearate and the balance of 70-80% of a filler; 5.5-10% of a disintegrating agent; 1-4% of a flow aid; and 1-4% of a lubricant. The finerenone orally disintegrating tablet disclosed by the invention is suitable for being taken by diabetics, and has the advantages of high disintegration and dissolution speed, stable finished product quality, no need of being taken with water and strong patient compliance; in addition, the finerenone orally disintegrating tablet disclosed by the invention is simple in preparation process, low in cost and suitable for large-scale production.

Provided are a freeze-dried flash release tablet of a GLP1 polypeptide drug and a preparation method therefor. The provided freeze-dried orally disintegrating tablet of a GLP1 polypeptide drug comprises the following raw materials in percentage by mass: 30%-50% of a GLP1 polypeptide-mEV stock solution, 0.1%-1.0% of a surfactant, 3%-5% of a framework agent, 1%-3% of an adhesive, 0.01%-1% of a suspending agent and the balance of water. The GLP1 polypeptide is one or more of liraglutide and semaglutide. Further provided is a method for preparing the freeze-dried flash release tablet of a GLP1 polypeptide drug. The flash release tablet is prepared by using a freeze-drying technique, and the obtained product has a large loading capacity and a good dissolution effect, which is beneficial to the oral absorption of the GLP1 polypeptide. In addition, the preparation method for the flash release tablet is simple and convenient, and is easy to implement.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The invention relates to the field of pharmaceutical preparations, and particularly discloses a celecoxib orally disintegrating tablet and a preparation process thereof. The invention relates to a preparation process of a celecoxib orally disintegrating tablet. The preparation method comprises the following steps: adding beta-cyclodextrin into deionized water, dissolving to obtain an emulsion, adding celecoxib into the emulsion, and stirring to obtain a matrix liquid; the preparation method comprises the following steps: adding bacterial cellulose into deionized water, adding ammonium carbonate, and carrying out vacuum filtration to obtain a fiber cake; dipping the fiber cake into an absolute ethyl alcohol solution of tetraethyl silicate, washing, drying and grinding to obtain a carrier; adding the carrier into the matrix liquid, stirring at room temperature, centrifuging, and freeze-drying the centrifugate to obtain an inclusion compound; uniformly mixing the inclusion compound with a filling agent, a slipping agent, an adhesive and a sweetening agent, adding pure water, stirring, emulsifying, vacuumizing, defoaming, sub-packaging into bubble caps, pre-freezing, freeze-drying and sub-packaging. The orally disintegrating tablet prepared by the invention is high in disintegration speed, convenient to take, slightly sweet in taste and high in medication compliance of patients.

The invention belongs to the technical field of medicines, and particularly relates to a melogabalin besylate orally disintegrating tablet coated with powder. The powder-coated melogabalin besylate orally disintegrating tablet provided by the invention has good wet stability, effectively masks the bitter taste of the raw material medicines, obviously improves the taste, has good dissolution behavior, shows extremely rapid dissolution in key media, is beneficial to the absorption of melogabalin besylate by the body, and can be used for preparing the oral disintegrating tablet for treating melogabalin besylate. The melogabalin besylate orally disintegrating tablet provided by the invention has a good application prospect.

The invention belongs to the technical field of medicine, and particularly relates to an aprepitant nanocrystalline composition and a preparation method and application thereof.The aprepitant and a sucrose solution are mixed, a stabilizer is added to obtain a solution to be ground, the solution to be ground is ground through a wet grinding process, and the aprepitant nanocrystalline composition is obtained; uniformly mixing the suspension with a spray drying protective agent and a flow aid to obtain a mixed solution, and drying and curing the mixed solution by adopting a spray dryer to obtain the aprepitant nanocrystal composition in the form of a dry suspension, and directly spray-drying the suspension, uniformly mixing the suspension with a skeleton agent and an adhesive, adding water to a constant volume, carrying out vacuum degassing, and carrying out pre-freezing and freeze-drying to obtain the freeze-dried orally disintegrating tablet type aprepitant nanocrystal composition.

The invention relates to the technical field of chemical pharmacy, in particular to a preparation method and application of troxerutin, and hydroxyethylation reaction is carried out on phenolic hydroxyl groups on a rutin flavone skeleton. Specific two-stage reaction is adjusted, and catalysts sodium hydroxide and sodium methoxide are selected in the first stage; in the second stage, the pH value is adjusted, and the high-purity and high-yield troxerutin is prepared under certain conditions by adopting a catalyst with a specific combination and a specific ratio, the purity can reach 99% or above after simple purification, and the yield reaches 93% or above. Furthermore, the invention also relates to an orally disintegrating tablet and a multi-layer slow-release dressing.

The invention discloses a valsartan-silicon dioxide micro-capsule orally disintegrating tablet and a preparation method thereof, and relates to the technical field of medicines. The invention relates to a preparation method of a valsartan-silicon dioxide micro-capsule orally disintegrating tablet. The preparation method comprises the following steps: S11, preparing an aqueous solution of a cationic surface active agent; s12, valsartan is added and stirred, so that the surface of valsartan is positively charged; s13, continuing to add silicon dioxide and stirring to enable a silicon dioxide monomer to be adsorbed on the surface of valsartan; and S14, continuously adding the cationic polymer and carrying out high-speed shearing, so that the cationic polymer is encapsulated on the surface of the silicon dioxide. The valsartan-silicon dioxide micro-capsule orally disintegrating tablet prepared by the invention has a medicine taste masking effect, and the taste masking effect is excellent; meanwhile, the problems of poor compressibility and flowability of materials caused by hygroscopicity and viscosity of valsartan are solved; a sweetening agent and a flavoring agent are not needed in the formula, so that the formula is simplified, impurities are prevented from being introduced into the essence, and the stability is effectively improved.

The application belongs to the technical field of pharmaceutical preparations, and specifically provides a kind of indobufen freeze-dried oral disintegrating tablet and a preparation method thereof.The freeze-dried oral disintegrating tablet contains indobufen and xanthan gum, and the freeze-dried oral disintegrating tablet can be obtained by freeze-drying technology after the above components are prepared into a suspension.The freeze-dried oral disintegrating tablet provided by the application has the technical characteristics of good properties, complete demolding, high drug loading, good content uniformity, rapid disintegration and rapid dissolution, and can meet the needs of rapid anti-platelet therapy in acute thrombosis events.

The invention provides a hematopoietic anti-aging active component extracted from fish embryos as well as an extraction method and application of the hematopoietic anti-aging active component, and belongs to the technical field of active component extraction. The hematopoietic anti-aging active component is extracted from fish embryos which are developed from fish fertilized eggs to the earlier stage of incubation at the optimum temperature and stop development through rapid freezing, and is rich in exosomes, active protein, peptide, chondroitin sulfate, hyaluronic acid, small molecule metabolites, various active factors and the like, and all the nutritional active components are matched with one another, so that the effects of resisting aging and resisting aging are achieved. The cartilage development can be supported, the joint health is ensured, the hematopoietic effect is enhanced, and the skin aging is delayed. The orally disintegrating tablet containing the hematopoietic anti-aging active component can avoid inactivation of bioactive substances caused by high temperature, and the biological activity of the hematopoietic anti-aging active component is reserved to the maximum extent. The hematopoietic anti-aging active component and the orally disintegrating tablet are simple in preparation process and remarkable in hematopoietic anti-aging effect.

1. Name of the product in this design: Pharmaceutical Packaging Box (Salbutamol Sulfate Orally Disintegrating Tablets for Children). 2. Purpose of this design: This design is used for packaging salbutamol sulfate orally disintegrating tablets. 3. The key design features of this product are the combination of pattern and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

The invention discloses a medicinal slow-release antistatic coating solution and a preparation method and application thereof, and belongs to the technical field of medicinal preparations, the medicinal slow-release antistatic coating solution comprises the following components by weight: 1.2-2.0% of an anti-sticking agent; 0.4%-0.8% of a plasticizer; 0.04 to 0.22% of a lubricant; 3.0 to 5.0 percent of ethyl cellulose; the balance is ethanol or an ethanol aqueous solution; and the lubricant is long-chain saturated fatty acid or long-chain saturated fatty glyceride with the carbon number of C12-C22. The coating liquid has an antistatic effect and can obviously improve electrostatic adsorption and particle bonding phenomena in the coating process, small-diameter medicine particles are coated by using the coating liquid, a prepared coating film is complete, smooth and crack-free, the slow-release effect is good, enteric slow-release particles and orally disintegrating tablets can be prepared after an enteric coating is further overlaid, and the application range is wide. And the preparation method has a good application prospect in the development of small-diameter functional particles and orally disintegrating tablets.

The present application belongs to the technical field of oral solid preparation, and particularly relates to a mosapride citrate orally disintegrating tablet and a preparation method thereof. Raw and auxiliary materials comprise mosapride citrate, a filling agent, a disintegrating agent, a glidant, a lubricant and a flavoring agent. The present application screens and optimizes the auxiliary material formula, adopts dry granulation, optimizes the preparation process, improves the compressibility and fluidity of the material, saves energy, improves the production quality and stability, makes the prepared orally disintegrating tablet disintegrate rapidly, has excellent taste, greatly improves the medication compliance of patients, simultaneously improves the drug dissolution and improves the bioavailability. In addition, compared with other types of solid oral preparations of the product, the mosapride citrate orally disintegrating tablet is particularly suitable for the elderly and patients with difficulty in swallowing, and provides convenience in special and urgent situations such as lack of drinking water for taking medicine.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an esdoxaban tosylate orally disintegrating tablet and a preparation method thereof. The ludoxaban tosylate orally disintegrating tablet is prepared from particles and external auxiliary materials, the particles comprise the following components: indedoxaban tosylate, a filler, a disintegrating agent 1, an adhesive and a solubilizer, the disintegrating agent 1 is a mixture of polyvinylpolypyrrolidone and croscarmellose sodium, and the adhesive is hydroxypropyl methylcellulose; the external auxiliary materials comprise the following components: a disintegrating agent 2, a flavoring agent, a coloring agent and a lubricating agent, wherein the disintegrating agent 2 is polyvinylpolypyrrolidone. The adhesive, the disintegrating agent and the asparaginic acid which are specifically combined are adopted to synergistically realize a rapid drug release effect, blank rapid granules do not need to be prepared, the preparation process is simpler, and meanwhile, the composition has the characteristic of good taste.

The present invention relates to an orodispersible tablet manufactured by a wet granulation method comprising pregabalin or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one binder, at least one glidant, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The invention discloses a rosaxostat orally disintegrating tablet and a preparation method thereof. The preparation method of the orally disintegrating tablet is selected from one of a freeze-drying method, a tabletting method and a melting method. The prescription of the freeze-drying method comprises the rosaxostat or rosaxostat salt, a skeleton supporting agent, an adhesive, a suspending aid and a surfactant. According to the preparation formula and the preparation process, the defect that the content uniformity of the prepared tablets is poor due to the fact that the uniformity of intermediate liquid medicine is poor in the preparation process can be overcome, and the disintegration time limit of the rosaxostat orally disintegrating tablets, especially the rosaxostat freeze-dried orally disintegrating tablets, is further prolonged; the medicine is especially suitable for old people, children, patients with dysphagia and people with inconvenience in taking water to take medicine; the bioavailability is high; the rosaxostat orally disintegrating tablet is simple in material, moderate in tablet weight, good in appearance, good in taste, fast in disintegration, simple in preparation process and suitable for industrial mass production.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an etoricoxib orally disintegrating tablet and a preparation method thereof. The etoricoxib orally disintegrating tablet comprises etoricoxib, a filling agent, a disintegrating stabilizer, a wetting agent and a lubricating agent, the disintegration stabilizer is composed of polacrilin potassium, diethylaminol and glycine. The preparation process adopts wet granulation. According to the invention, the problem of balance among disintegration speed, stability and taste of the traditional orally disintegrating tablet is solved, and the orally disintegrating tablet has clinical transformation value.

The invention provides an amlodipine besylate orally disintegrating tablet and a preparation method thereof, and the preparation method comprises the following steps: mixing a diluent, adding a binder aqueous solution for granulation, and then drying to obtain blank particles; adding an additional material into the blank particles, and uniformly mixing to obtain total mixed particles; and tabletting the total mixed particles to obtain the amlodipine besylate orally disintegrating tablet. Wherein the additional material is amlodipine besylate and one or more of a diluent, a disintegrating agent, an opacifying agent, a sweetening agent and a lubricant. According to the scheme, by preparing the blank particles and adopting the form of externally adding the raw material medicines, the raw material medicines are prevented from being subjected to heat-moisture treatment, and the blank particles and the externally added materials are mixed and then tableted, so that the stability of the product is improved, the impurity content is reduced, the flowability and bulk density of the particle mixed powder are superior to those of the mixed powder, and the next tableting procedure is facilitated; and the chip weight stability is ensured.

The present invention relates to an orodispersible tablet comprising carbamazepine or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one binder, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients 5 exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The application provides a folic acid-containing composition and application, an orally disintegrating tablet and a preparation method. The folic acid-containing composition comprises folic acid raw materials, escitalopram oxalate and memantine hydrochloride. The weight ratio of the folic acid raw materials, the escitalopram oxalate and the memantine hydrochloride is (0.4-5):(10-20):(5-30). The folic acid raw materials comprise one or more of folic acid and derivatives thereof. The folic acid raw materials, the escitalopram oxalate and the memantine hydrochloride are used in a specific proportion, can be synergistic, can effectively treat post-stroke central neuropathic pain with depression, and can prevent recurrence of stroke, and are beneficial to post-stroke rehabilitation.

The invention provides a folic acid-containing composition and application thereof, an orally disintegrating tablet and a preparation method, the folic acid-containing composition comprises a folic acid raw material, escitalopram oxalate and melogabalin besylate, and the weight ratio of the folic acid raw material to escitalopram oxalate to melogabalin besylate is (0.4-5): (10-20): (5-30). The folic acid raw materials comprise one or more of folic acid and derivatives thereof. Folic acid raw materials, escitalopram oxalate and melogabalin besylate are used in a matched mode according to a specific proportion, synergistic interaction can be achieved, central nervous pathological pain accompanied by depression after stroke can be effectively treated, meanwhile, relapse of stroke can be prevented, and rehabilitation after stroke is facilitated.

The invention discloses a preparation method for prolonging the validity period of erythromycin ethylsuccinate orally disintegrating tablets. The preparation method comprises the following steps: sequentially putting low-substituted hydroxypropyl cellulose, microcrystalline cellulose, aspartame, carboxymethyl starch sodium and polyvinylpolypyrrolidone into a wet granulation mixer, covering with a cover, starting equipment, carrying out low-speed dry mixing for 3 minutes, slowly adding low-concentration hydroxypropyl methylcellulose slurry from a feed port of a pot cover, and carrying out low-speed wet mixing for 3 minutes; stopping the machine, opening the cover, scraping powder on the inner surface of the pot cover and the periphery of the inner side of the pot by using a clean scraper, adding erythromycin ethylsuccinate raw materials, covering the cover, starting equipment, carrying out low-speed wet mixing for 3 minutes, and carrying out high-speed wet mixing for 2 minutes. By improving the medicine production process, the stability and durability of the medicine are improved, so that the validity period of the medicine is prolonged, and meanwhile, the effectiveness and safety of the medicine can still be kept within the prolonged validity period.

The present invention discloses a buclizine hydrochloride orally disintegrating tablet composition and a preparation method thereof, which relates to the technical field of preparations. The buclizine hydrochloride orally disintegrating tablet composition, calculated by weight parts, comprises the following components: 4 parts of buclizine hydrochloride fine powder, 60-100 parts of a diluent, 10-30 parts of a disintegrant, 0.5-2 parts of a binder, 1-3 parts of a glidant, 1-5 parts of a sweetening agent, 0.5-5 parts of a lubricant, and 0.5-1.5 parts of a solubilizer. The present invention uses buclizine hydrochloride in combination with a solubilizer, so that the dissolution of buclizine hydrochloride is greatly improved. In combination with other components in the material, low-substituted hydroxypropyl cellulose and cross-linked polyvinylpyrrolidone, the disintegration time limit is further improved.

A cellulose composition containing cellulose, glucose and sorbitol, wherein a total content of glucose and sorbitol is 0.7 mg or more and 4.0 mg or less per 5 g of the cellulose composition. A tablet contains the cellulose composition. An orally disintegrating tablet contains the cellulose composition.